First, Alzheimers disease and other dementias are strongly linked to metabolic dysfunctionespecially insulin resistance in the brain, sometimes labeled type 3 diabetes. Second, a class of diabetes and weight-management medicines called GLP-1 receptor agonists (GLP-1 RAs) shows early but increasingly consistent signals that they may lower dementia risk in people with type 2 diabetes, and possibly slow specific biological changes of Alzheimers in small clinical trials
Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al
One group received only the medications, another received the medications plus ALC, and the third group received placebo
Lets look at some common myths
Sourcing Research-Grade Retatrutide What Research-Use-Only Actually Means "Research use only" is a regulatory and labeling designation, not a marketing description
CrossRef Varices and Hemorrhagic Events during Atezolizumab-bevacizumab Treatment: Reassurance with Caveats for Prognosis Hae Lim Lee Gut and Liver .2026